| Literature DB >> 33791287 |
Weifeng Li1, Zhenlin Fan2, Yan Lin2, Tian-Yun Wang1,2.
Abstract
At present, nearly 70% of recombinant therapeutic proteins (RTPs) are produced by Chinese hamster ovary (CHO) cells, and serum-free medium (SFM) is necessary for their culture to produce RTPs. In this review, the history and key components of SFM are first summarized, and its preparation and experimental design are described. Some small molecule compound additives can improve the yield and quality of RTP. The function and possible mechanisms of these additives are also reviewed here. Finally, the future perspectives of SFM use with CHO cells for RTP production are discussed.Entities:
Keywords: Chinese hamster ovary cells; cell culture; glycosylation; recombinant therapeutic protein; serum free medium
Year: 2021 PMID: 33791287 PMCID: PMC8006267 DOI: 10.3389/fbioe.2021.646363
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Development and characteristic of SFM.
| SFM | A variety of biological materials that can replace the function of serum, contains a large number of plant and animal protein and unknown components, such as bovine serum albumin or α- or β-globulin, used as a supplement. |
| XFM | Human-source components, such as human serum albumin, are used as supplements but animal components are not allowed as supplements. |
| AFM | No animal source proteins, and the required proteins are derived from recombinant proteins or proteolytic proteins. |
| PFM | No serum at all, no protein or low protein content, contains undefined components such as peptide components (hydrolyzed proteins). |
| CDM | No serum, no protein, chemical defined component; suitable for different cells growth and recombinat protein production. |
The composition of SFM.
| Energy sources | Carbon sources | Glucose | Fucose/Galactose/Mannose/Maltose/Gluconeogenic pathway etc. |
| Amino acids | Nitrogen sources | EAA/NEAA (Asparagine/) Glutamine | Synthetic amino acid/Peptide compound. |
| Vitamin | Maintains cell growth | WSV/FSV (vitamin C/E) | |
| Lipid | Energy storage substance/signal transduction | SFA/USFA | Linoleic acid/Oleic acid/Ethanolamine/Choline etc. |
| Trace elements | Cell metabolism/Enzyme | Fe/Se/Cu/Zn | |
| Anti-shear protectant | Prevent cell damage. | Shearing force/P-F68 | Surfactant/Reduce shear force. |
| Inorganic saltion | Stable osmotic pressure | Na/K/Mg/Ca/P | Cell physiological activities/Intercellular substance/Cell metabolism/Physiological functions. |
| Nucleic acid substances | Signaling pathway blocking | Hypoxanthine/Thymidine | |
| Others | Promoting cell growth and protein expression | Transferrin/Fe/growth factor. | NaB/antioxidants; Specific production/expression rate of tPA. |
FIGURE 1Optimization and preparation of serum-free culture screening process.
FIGURE 2Example of Plackett–Burman design for medium optimization and results. (A) Seventeen tests of Plackett–Burman design including three components at two concentration; (B) Response surface results of 17 tests.
Summary of additives of different mechanism components.
| Cell growth | DS (15,000 Da) | 5.23 ± 0.10 | 13.7 ± 0.80 | 390.1 ± 17.5 | |
| EGCG 7/8 mM | 16 ± 0.10 | 16 ± 0.50 | 600∼800 | ||
| IGF-1 | >Control | ||||
| Resveratrol 25/50 μM | 10 ± 1.20 | 4.7 ± 0.6 | 0.203 ± 0.004 | ||
| … | … | … | … | … | |
| Cell cycle | valeric acid1.5 mM | 1.87 ± 0.05 | 45.6 ± 5.1 | 0.87 ± 0.31 | |
| Catechins | 16 ± 0.10 | 16 ± 0.50 | 600∼800 | ||
| VPA 25 mM | ∼1 ± 0.55 | ∼10 ± 1.20 | ∼200 | ||
| … | … | … | … | …. | |
| Cell metabolim | Glutamine | 2000 ± 0.55 | 2440 ± 86 | 87.4 ± 1.2 | |
| α-KG 2 mM | 1.43 | 6.2 μg | 0.0165 | ||
| DCA 5 mM | 7.47 | 8.80 ± 0.12 | 0.138 | ||
| … | … | … | … | … | |
| Cell apoptosis/autophagy | NaB 5 mM | ∼6.15 | 0.11 | ||
| Suramin 5 mM | 5.16 ± 0.1 | 0.16 | |||
| 3-MA 5 mM | three-fold | 2.8-fold | 2.8-fold | ||
| … | … | … | … | …… | |
| Glycosylation | Balcalein (DMSO) 100 μM | 2.35 ± 0.06 | 22.13 ± 2.20 | 0.901 ± 0.112 | |
| Raffinose 30 mM | 9.2 | 1.2 ± 0.22 | 4.2 | ||
| Mannose | 35 | 2.13 ± 0.05 | 9 | ||
| Zinc150 μM | ∼5 ± 0.10 | ||||
| … | … | … | … | …. | |
| Multiple mechanism combination | 1,3,4-O-Bu3–ManNAc + glycoengineering | ∼3 | ∼1.8-fold | ∼2-fold | |
| All trans carboxylic acid (100 nM) + NaB (0.5 mM) (30°C) | ∼4.6 | 55 ± 0.03 | 0.0075 ± 0.0003 | ||
| NaB (30°C) | ∼1.8 | 23 ± 0.11 | 170 mg/L | ||
| NaB (30°C) + GF | 7.9 | 18.5 ± 4.7 | 0.3 ± 0.05 | ||
| … | … | … | … | … |